Literature DB >> 34354193

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease.

Taeang Arai1, Masanori Atsukawa2, Akihito Tsubota3, Keizo Kato4, Hiroshi Abe4, Hirotaka Ono1, Tadamichi Kawano1, Yuji Yoshida5, Tomohide Tanabe1, Tomomi Okubo5, Korenobu Hayama5, Ai Nakagawa-Iwashita1, Norio Itokawa1, Chisa Kondo1, Keiko Kaneko1, Naoya Emoto6, Mototsugu Nagao7, Kyoko Inagaki7, Izumi Fukuda7, Hitoshi Sugihara7, Katsuhiko Iwakiri1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is related to subclinical atherosclerosis. However, whether the severity of the disease (or which histopathological component) is associated with subclinical atherosclerosis remains controversial. This study aimed to investigate the association between the histopathological severity of NAFLD and carotid intima-media thickness (CIMT) in Japanese patients with liver biopsy-proven NAFLD. Maximum-CIMT (max-CIMT) was measured as an index of carotid atherosclerosis in 195 biopsy-proven NAFLD patients. A significant association was observed between the severity of fibrosis (but not steatosis, inflammation, and ballooning) and max-CIMT. Older age, male gender, hypertension, and advanced fibrosis were independently linked to max-CIMT ≥ 1.2 mm. The prevalence of max-CIMT ≥ 1.2 mm was significantly higher in the advanced fibrosis group than in the non-advanced fibrosis group (75.4% versus 44.0%; p < 0.01). Non-invasive liver fibrosis markers and scoring systems, including fibrosis-4 index, NAFLD fibrosis score, hyaluronic acid, and Wisteria floribunda agglutinin positive Mac-2-binding protein, demonstrated that the diagnostic performance for max-CIMT ≥ 1.2 mm was similar to that of biopsy-based fibrosis staging. In conclusion, advanced fibrosis is significantly and independently associated with high-risk CIMT. Non-invasive fibrosis markers and scoring systems could help estimate the risk of atherosclerosis progression in patients with NAFLD.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34354193     DOI: 10.1038/s41598-021-95581-8

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  59 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

2.  Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Authors:  Hannes Hagström; Patrik Nasr; Mattias Ekstedt; Ulf Hammar; Per Stål; Rolf Hultcrantz; Stergios Kechagias
Journal:  J Hepatol       Date:  2017-08-10       Impact factor: 25.083

3.  Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Authors:  Mattias Ekstedt; Hannes Hagström; Patrik Nasr; Mats Fredrikson; Per Stål; Stergios Kechagias; Rolf Hultcrantz
Journal:  Hepatology       Date:  2015-03-23       Impact factor: 17.425

Review 4.  A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?

Authors:  Ebenezer T Oni; Arthur S Agatston; Michael J Blaha; Jonathan Fialkow; Ricardo Cury; Andrei Sposito; Raimund Erbel; Ron Blankstein; Ted Feldman; Mouaz H Al-Mallah; Raul D Santos; Matthew J Budoff; Khurram Nasir
Journal:  Atherosclerosis       Date:  2013-08-09       Impact factor: 5.162

Review 5.  Nonalcoholic fatty liver disease: from steatosis to cirrhosis.

Authors:  Geoffrey C Farrell; Claire Z Larter
Journal:  Hepatology       Date:  2006-02       Impact factor: 17.425

Review 6.  Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis.

Authors:  Javier Ampuero; Rocío Gallego-Durán; Manuel Romero-Gómez
Journal:  Rev Esp Enferm Dig       Date:  2015-01       Impact factor: 2.086

Review 7.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

8.  Nonalcoholic fatty liver disease contributes to subclinical atherosclerosis: A systematic review and meta-analysis.

Authors:  Yao-Yao Zhou; Xiao-Dong Zhou; Sheng-Jie Wu; Dan-Hong Fan; Sven Van Poucke; Yong-Ping Chen; Shen-Wen Fu; Ming-Hua Zheng
Journal:  Hepatol Commun       Date:  2018-02-26

Review 9.  Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease.

Authors:  Andrew A Li; Aijaz Ahmed; Donghee Kim
Journal:  Gut Liver       Date:  2020-03-15       Impact factor: 4.519

10.  Improved survival after treatments of patients with nonalcoholic fatty liver disease associated hepatocellular carcinoma.

Authors:  Jihane N Benhammou; Elizabeth S Aby; Gayaneh Shirvanian; Kohlett Manansala; Shehnaz K Hussain; Myron J Tong
Journal:  Sci Rep       Date:  2020-06-18       Impact factor: 4.379

View more
  4 in total

1.  Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Authors:  Qian Jin; Rui-Xu Yang; Jian-Gao Fan
Journal:  Clin Mol Hepatol       Date:  2022-06-22

2.  Association of Oxidized Low-Density Lipoprotein in Nonalcoholic Fatty Liver Disease with High-Risk Plaque on Coronary Computed Tomography Angiography: A Matched Case-Control Study.

Authors:  Takahiro Nishihara; Toru Miyoshi; Keishi Ichikawa; Kazuhiro Osawa; Mitsutaka Nakashima; Takashi Miki; Hiroshi Ito
Journal:  J Clin Med       Date:  2022-05-17       Impact factor: 4.964

Review 3.  Oxidized Lipids: Common Immunogenic Drivers of Non-Alcoholic Fatty Liver Disease and Atherosclerosis.

Authors:  Constanze Hoebinger; Dragana Rajcic; Tim Hendrikx
Journal:  Front Cardiovasc Med       Date:  2022-01-10

4.  Non-alcoholic/Metabolic-Associated Fatty Liver Disease and Helicobacter pylori Additively Increase the Risk of Arterial Stiffness.

Authors:  Ji Min Choi; Hyo Eun Park; Yoo Min Han; Jooyoung Lee; Heesun Lee; Su Jin Chung; Seon Hee Lim; Jeong Yoon Yim; Goh Eun Chung
Journal:  Front Med (Lausanne)       Date:  2022-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.